Otsuka Pharma sets up joint venture in Turkey

7 November 2012

Otsuka Pharmaceutical (TYO: 4768), a mid-size Japanese drugmaker, and Abdi brahim have established a joint venture in Turkey, to be called Abdi Ibrahim Otsuka Pharmaceutical AS, with 50% of  investment each from the two partners.

Abdi Ibrahim Otsuka Pharmaceutical will be marketing and selling Otsuka’s innovative drugs that have been produced as the result of the Japanese firm’s R&D. In that respect, the new company aims to present many innovative pharmaceuticals in various treatment fields to the service of the Turkish Public in order to serve the well-being in Turkey.

Turkey a promising pharma market

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical